Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Income from Continuing Operations of 52860000.0 for Q1 2026, up 65.83% year-over-year from 31876913.74 in Q1 2025, and down 65.47% quarter-over-quarter from 31946000.0 in Q4 2025.
Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Income from Continuing Operations for 7 consecutive years, with 52860000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 65.83% year-over-year to 52860000.0; the TTM figure through Mar 2026 stood at 348498000.0 (up 56.94% YoY), while the FY2025 annual figure was 143221000.0, up 66.74% from the prior year.
- Income from Continuing Operations retreated to 52860000.0 in Q1 2026 per JANX's latest filing, from 31946000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11758000.0 in Q4 2023 and bottomed at 341545000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 102802235.29 across 5 years, with a median of 54414000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 2020.58% — and 2026, when it soared 65.83%.
- Janux Therapeutics' Income from Continuing Operations stood at 16409000.0 in 2022, then climbed by 28.34% to 11758000.0 in 2023, then plunged by 71.93% to 20216000.0 in 2024, then plunged by 58.02% to 31946000.0 in 2025, then slumped by 65.47% to 52860000.0 in 2026.
- Business Quant data shows JANX's Income from Continuing Operations at 52860000.0 in Q1 2026, 31946000.0 in Q4 2025, and 131157000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -60.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.55 Mn |
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -131.16 Mn |
| Jun 30, 2025 | -132.54 Mn |
| Mar 31, 2025 | -154.68 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -341.55 Mn |
| Jun 30, 2024 | -292.84 Mn |
| Mar 31, 2024 | -268.52 Mn |
| Dec 31, 2023 | -11.76 Mn |
| Sep 30, 2023 | -26.64 Mn |
| Jun 30, 2023 | -54.12 Mn |
| Mar 31, 2023 | -54.89 Mn |
| Dec 31, 2022 | -16.41 Mn |
| Sep 30, 2022 | -54.41 Mn |
| Jun 30, 2022 | -54.68 Mn |
| Mar 31, 2022 | -48.43 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -83.44 Mn |